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Stem cells are defined by their capabilities to self-renew and give rise to various types
of differentiated cells depending on their potency. They are classified as pluripotent,
multipotent, and unipotent as demonstrated through their potential to generate the
variety of cell lineages. While pluripotent stem cells may give rise to all types of cells
in an organism, Multipotent and Unipotent stem cells remain restricted to the particular
tissue or lineages. The potency of these stem cells can be defined by using a number
of functional assays along with the evaluation of various molecular markers. These
molecular markers include diagnosis of transcriptional, epigenetic, and metabolic states
of stem cells. Many reports are defining the particular set of different functional assays,
and molecular marker used to demonstrate the developmental states and functional
capacities of stem cells. The careful evaluation of all these methods could help in
generating standard identifying procedures/markers for them.
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INTRODUCTION
Stem cells are unique in their capabilities to either self-renew or differentiate into various cell
lineages. The most primitive stem cells have the potential to generate all the cell types in any
organism and termed as pluripotent stem cells (PSCs) (Hanna J. H. et al., 2010). Whereas,
multipotent and unipotent stem cells are defined to bear limited self-renewing capacity and these
cells, differentiate into a particular tissue type or cell lineage. It is important to notice that cells
derived from fertilized egg (zygote/blastomeres) have the potential to generate all the embryonic
and extra-embryonic cells; potential referred to as totipotency and thus can give rise to the whole
organism, however their developmental potential remains undefined in vitro (Kelly, 1977). Both
human and mouse derived Embryonic Stem Cells (ESCs) are demonstrated to generate all types
of cells, but lack potential to contribute to the extra-embryonic cells such as placenta. These cells
are termed as PSCs and have various functional properties depending on their culture conditions.
Another important class of stem cells is lineage specific multipotent stem cells [e.g., Hematopoietic
Stem Cells (HSCs)] which have limited differentiation potential and develop only in their tissue/cell
types. The multipotent stem cells do not differentiate into cell types of different tissue origin under
normal physiological circumstances. The developmental potential of unipotent stem cells is further
restricted and they remain able to give rise to only a single cell type (for example, blast forming
unit-erythroid (BFU-E) may be differentiated into erythrocytes).
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Thus, the traditional developmental dogma follows the
differentiation of totipotent stem cells to PSCs, PSCs to
multipotent stem cells, multipotent stem cells to unipotent stem
cells and finally mature cells. Both the self-renewal capacity
and differential potential are reduced during their journey
from totipotent to mature cell state. However, the discovery of
nuclear reprogramming methods such as somatic cell nuclear
transfer method and use of transcriptional factors to induce
pluripotency in any cell type are demonstrated as powerful tools
to reverse this hierarchy (Gurdon, 1962; Kato and Tsunoda, 1993;
Campbell et al., 1995, 1996; Wilmut et al., 1997; Kato et al.,
1998; Wakayama et al., 1998; Wakayama and Yanagimachi, 1999;
Takahashi and Yamanaka, 2006; Takahashi et al., 2007). These
findings show that the particular state of a somatic cell can
be reprogrammed to achieve a totipotent or pluripotent state.
iPSC generated from patients have great potential in disease
modeling and regenerative medicine (reviewed by Singh et al.,
2015). It is clear that defining various fundamental levels of
pluripotency states (e.g., naïve vs. prime etc.) remain central
in developing various strategies for their clinical/research uses
and therefore it is important to rigorously evaluate the different
methods/molecular markers etc. reported so far for the various
PSCs types.
A comprehensive review of all the functional assays defining
the pluripotent states of stem cells would be of great importance
to assess the functional applications and reprogramming
efficiency of different methods and cell sources that are being
explored both in clinical and research settings. Recently, many
researchers have developed few alternative approaches such as in
silico analysis to detect pluripotency or differentiation potential
of any existing or new cell for clinical and research purposes
(Sato et al., 2003; Sperger et al., 2003; Bhattacharya et al.,
2004; Suárez-Farinas et al., 2005; Müller et al., 2008). It would
be of great importance to have more concrete definitions and
defining markers to demonstrate the significance of these in
silico approaches and decide the clinical utility of the particular
cell population that is to be used. Present article focuses on
the various molecular markers and diagnostic strategies being
used to define the exact state of any given cellular population
that is assumed to be pluripotent or multipotent and may
be used further in any relevant clinical/research regime. As
discussed in the later sections, there are many molecular
markers (including TFs e.g., OCT4, SOX4, NANOG etc.; micro
RNAs, Transcriptional regulators and epigenetic chromosomal
modifiers, etc.; discussed in detail in later sections) that are
promptly used for a quick evaluation of cellular potency by
most researchers/clinicians. Although, the complexity associated
with the definition of the actual state of pluripotency (e.g.,
ground state, naïve, and prime states of pluripotency etc.) and
the incapability of individual “pluripotency-defining molecular
markers” which often remain doubtful, has raised the demand
for identification of more conspicuous definitions and diagnostic
tools. Since then, functional assays have remained the gold
test for defining pluripotency of all types of stem cells in
vertebrates. There are a variety of functional assays which
differ both in the time and effort taken to perform them and
the accuracy of the results obtained from these assays. The
different studies done in mice, human, and other mammals
have been useful to define the functional assay in different
categories.
Pluripotent Stem Cells: The Definition
The standard definition of PSCs relies on the fact that they
can produce all three germ cell layer cells and thus can give
rise to almost all types of cells in the body (Table 1; Hanna
J. H. et al., 2010). However, PSCs seem to lack capabilities of
producing extra embryonic cells and thus may not contribute
to the development of placental cells. These PSCs is therefore
different from Totipotent stem cells (capable of giving rise to
extra-embryonic tissue also) since they may not be developed
into a complete organism. Another important feature for
defining pluripotency has been their capabilities to self-renew
themselves. However, recent studies revealed that PSCs can be
maintained in self-renewing states in vitro indefinitely through
a number of growth factors/exogenous signals indicating that
the self renewing capacity may not be the defining hallmark of
pluripotency (Nichols and Smith, 2012). Studies done by using
various types of pluripotent cells indicated that pluripotency is
more accurately defined as a transient and dynamic state in vitro
and different types of PSCs can be derived from different stages
of developing embryos in vertebrates. The pluripotency of these
cells is reflected through the expression of TFs, assessment of
genomic integrity, and their capability to differentiate robustly
into all 3 cell lineages.
There are multiple types of PSCs (including rodents, humans
and primates) that are typically classified on the basis of their
origin from a specific tissue (Figure 1) such as various germline
tumors, blastomeres, and inner cell mass of developing embryos
(Box-1). Somatic cell reprogramming techniques gave alternative
tools for generating PSCs both in mouse and humans. Somatic
cells have been reported to become ESCs-like byNuclear Transfer
resulting into NT-ESCs (Wakayama et al., 2001; Tachibana et al.,
2013; Yamada et al., 2014). Similarly, PSCs can be derived
by inducing reprogramming through ectopic expression of a
number of different TFs (Takahashi and Yamanaka, 2006).
The ectopic expression of basal reprogramming factors (OCT4,
KLF4, SOX2, and c-MYC) in the mouse fibroblasts led to their
reprogramming into pluripotent cells, which were called as
induced pluripotent stem cells (iPSCs; Takahashi and Yamanaka,
2006). The generation of these iPSCs came out as breakthrough
as it gave a way of generating PSCs from somatic cells without
having any requirement of ESCs which have associated ethical
concerns. Since then, researchers all over the world have used
this technique to reprogramme different somatic cell types into
iPSCs (Yu et al., 2007). Many groups have also reported different
approaches to reprogramming, which include the exclusion or
replacement of one or more of the basal 4 reprogramming
factors, along with the inclusion of different small molecules
that have been reported to increase the reprogramming efficiency
(Feng et al., 2009). IPSCs pose to have many applications in
the stem cell therapies, drug toxicity assays, disease modeling,
gene therapy, and hence they hold great importance (Singh et al.,
2015).
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TABLE 1 | Differentiation of PSCs in all the three cell lineage.
Pluripotent cell used Germ layer Tissue Organism References
Mouse embryonic stem (ES) cells Endoderm Hepatocytes Mouse Hamazaki et al., 2001
Murine embryonic stem (ES) cells Endoderm Hepatocytes Murine Jones et al., 2002
Embryoid bodies (EBs) Endoderm Hepatocytes Mice Yamada et al., 2002a
Embryonic stem cells Endoderm Early Pancreas Human Colman, 2004
Murine embryonic stem cells Endoderm Early Pancreas Murine Ku et al., 2004
Mouse embryonic stem (ES) cells Endoderm Thyrocytes Mouse Lin et al., 2003
Murine embryonic stem cells Endoderm Type II Pneumocytes Murine Ali et al., 2002
Mouse embryonic stem (ES) cells Endoderm Intestinal cells Mouse Yamada et al., 2002b
Human embryonic stem cells Mesoderm Hematopoietic Human Kaufman et al., 2001
Mouse yolk Sac Mesoderm Vascular Mouse Haar and Ackerman, 1971
Human embryonic stem cells Mesoderm Cardiac Human Nir et al., 2003
Mouse embryonic stem (ES) cells Mesoderm Cardiac Mouse Hescheler et al., 1997
Mouse embryonic stem (ES) cells Mesoderm Cardiac Mouse Min et al., 2002, 2003
Mouse embryonic stem (ES) cells Mesoderm Skeletal Muscle Mouse Rohwedel et al., 1994
Murine embryonic stem cells Mesoderm Osteogenic Murine Buttery et al., 2001
Mouse blastocyst Mesoderm Osteogenic Mouse Zur Nieden et al., 2003
Mouse embryonic stem (ES) cells Mesoderm Chrondrogenic Mouse Kramer et al., 2000
Murine embryonic stem cells Mesoderm Adipogenic Murine Dani et al., 1997
Mouse embryonic stem (ES) cells Ectoderm Neuroepithelium Mouse Li et al., 1998
Human embryonic stem cells Ectoderm Neural Cells Human Reubinoff et al., 2001; Zhang et al., 2001
FIGURE 1 | Classification of various types of pluripotenct stem cells on the basis of their origin. Various types of pluripotent stem cells can be classified on
the basis of their origin or source from where they are taken and this would directly define their self-renewing and differentiation potential. Pluripotency of stem cells is
also regulated through their culture microenvironment and they are often named on the basis of their similarity to the various types of previously established PSCs e.g.,
ICM-like or ES-like PSCs. [Mouse (+), Human (+) indicates derivation of ESCs inthese mammals; Human(−) indicates non-derivation of post-implantation EPIsc in
humans].
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BOX 1 | MULTIPLE TYPES OF PSCS IN MOUSE AND HUMANS
Mouse pluripotent stem cells
Initially, Stevens and his colleagues demonstrated the formation of
teratocarcinoma cells by using strain 129 mice model and thus in vitro
methods for the propagation of ESCs derived from similar mice model
studies was established (Stevens, 1958). Subsequently, methods for the
propagation of immortalized non-transformed embryonic stem cell lines
were demonstrated by growing cells derived from murine blastocysts
preconditioned media with preformed teratocarcinoma stem cell line (Evans
and Kaufman, 1981; Martin, 1981). This method of obtaining ESCs was
followed by some researchers for the isolation of pluripotent cells lines from
various types of sources (Thomson et al., 1995). Initial studies suggested that
mouse ESCs could only be obtained from the embryo before implantation
in the uterus. However, later reports established that rodent ESCs can be
derived from the post-implantation embryo (epiblast tissue) that generates
the embryo proper (Brons et al., 2007; Tesar et al., 2007). These cells are
referred as EpiSCs (post-implantation epiblast-derived stem cells), and can
be derived by culturing cells in chemically defined media along with other
supplements (Brons et al., 2007; Tesar et al., 2007). For ethical reason similar
EpiSCs are not attempted in humans so far.
Early migrating mouse PGCs are shown to have pluripotent ESC-like
properties when grown in vitro under specific conditions and termed as
embryonic germ cells (Matsui et al., 1992; Leitch et al., 2010). The mouse
PGCs were grown up to 20 passages in the presence of “Steel Factor”
(membrane-associated SF) and “Leukemia Inhibitory Factor” (LIF) and bFGF
supporting their continued proliferation. The cells exhibit pluripotency through
the generation of embryoid bodies and multiple differentiated cell phenotypes
in monolayer culture and tumors in nude mice, and can also contribute to
chimeras when injected into host blastocysts (Matsui et al., 1992; Leitch et al.,
2010).
The successful establishment of ES-like cells has been reported from
neonatal mouse testis exhibiting phenotypic similarities to ESCs/EGCs
except in their genomic imprinting pattern (Kanatsu-Shinohara et al., 2004).
In similar studies, adult unipotent germline stem cells (GSCs) was reported to
be capable of differentiating into multiple cell types both by in vivo and in vitro
assays, including germ cell contribution and transmission (Ko et al., 2009).
There have been efforts to define marker profiling of ESCs and it is shown
that ESCs are distinct from early inner cell mass (ICM) and closely resemble
preimplantation epiblast (Boroviak et al., 2014).
Many studies have revealed manifestation of distinct features
of various types of PSCs attributed to their origin and
maintenance conditions (Figure 1). Depending on their origin,
they are coined with different terms such as ESCs (established
from pre-implanted embryos) and Epiblast stem cells or EpiSCs
(generated from later embryonic epiblast stages; Figure 1; Brons
et al., 2007; Tesar et al., 2007). They are also often termed as
“naïve” (for ESCs) and “primed” (for EpiSCs) pluripotent stem
cells to highlight their early and late phases of development
(Nichols and Smith, 2009). The mouse “naïve” and “primed”
ESCs differ in their capacity to form high-grade chimeras with
naïve ESCs being able to form chimeras but primed ESC remain
incapable. However, the difference in the chimera forming
capabilities of naïve and primed PSCs could be attributed to the
use of suboptimal regimes for chimera generation experiments
and development of more defined protocols by addition of
some regulatory factors (e.g., FGF-4) may improve the chimera
forming efficiency of even primed PSCs in mouse at least (Joo
et al., 2014). The conventional human PSCs (hESCs) look similar
to EpiSC by their molecular markers thus called as “primed”
ESCs. However, “naïve” pluripotency may not be evaluated in
hESCs due to ethical restriction on the formation of human
chimeras. Nevertheless, existence of a naïve state of pluripotency
in hESCs has been reported recently, and it is believed that
the pluripotency of hESCs also can be enhanced by genetic
modification or optimized culture systems (Buecker et al., 2010;
Hanna J. et al., 2010; Lengner et al., 2010; Xu et al., 2010; Gafni
et al., 2013). The nonhuman primates ESCs have been assessed
for naïve pluripotency showing their inability to form a chimera
with pre-implantation embryos (Tachibana et al., 2012).
EVALUATION OF PLURIPOTENCY
THROUGH MOLECULAR MARKER
PROFILING AND FUNCTIONAL ASSAYS
Development of Various Molecular
Diagnostics for PSCs
The pluripotency of cells is mainly governed by a number
of molecular mechanisms which regulate the expression of
genes responsible for the maintenance of primitive stages
and repression of differentiation. There are a number of key
molecules which sustain the self-renewal, but inhibit the genes for
differentiation or keep them silent till external stimuli inducing
differentiation activates them. Few important TFs are playing the
crucial role in the maintenance of pluripotency, and it is their
expression level which defines the pluripotency in various types
of ESCs/EpiSCs (Figure 2).
For example, the basal four reprogramming factors OCT4,
SOX2, KLF4, and c-MYC (OSKM) were found to be able to
induce somatic cells reprogramming and are often correlated
with the pluripotency state of any cell population. All of these
factors have their own important role in the generation and
regulation of pluripotency in the PSCs. For example, OCT4 is
the most important reprogramming factor of these four. Loss
of OCT4 in embryos lacking Smad2 results into premature
differentiation of epiblast which supports the role of OCT4 as an
exclusive pluripotencymarker and further suggests its crucial role
in the development of pluripotency in ICM and its maintenance
in ESCs (Waldrip et al., 1998). Similarly, SOX2 is important
for various development processes such as maintenance of
“stemness” in neural progenitor cells and its removal lead to
their differentiation (Graham et al., 2003). The main role of
SOX2 is the regulation of pluripotency and the determination
of cell fate. KLF4 is a mediator of LIF-Stat3 signals and it helps
OCT4 and SOX2 in the regulation of NANOG by binding to
the promoter of NANOG which also plays a crucial role in
the maintenance of pluripotency (Zhang et al., 2010). c-MYC
has been responsible for the promotion of active chromatin
environment, and enhancement of cell proliferation. It also has
an important role in the enhancement of the transition that
occurs from the initiation to elongation of the transcription. It
has been found to be having an important role in the early stages
of the induction as evidenced from the enhanced generation of
partially reprogrammed cells, which have not yet turned on the
genes for OCT4, SOX2, and KLF4 (Schmidt and Plath, 2012).
Further, it has been reported that some molecular markers
such as stage specific embryonic antigen-1 (SSEA1) and alkaline
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FIGURE 2 | Molecular diagnostics for determination of Pluripotency. Various research groups have demonstrated the molecular markers especially TFs which
essentially regulate the self-renewal and differentiation potential of PSCs. These factors either directly regulate renewal/ differentiation through their binding to the
target gene and therefore regulating target gene expression; or they themselves get regulated and are the target for a number of other transcription regulating
elements such as miTNA, Noncoding RNA, Histone modifiers. Various researchers have wisely used these factors as the marker to define the potential of any test
cells as an alternate approach to the standard functional assays.
phosphatase get induced in very early stages of reprogramming.
Few of the SSEA1+ cell give rise to reprogrammed cells through
the activation of OCT4, SOX2, and NANOG (Ho et al., 2011).
Many reports demonstrate their particular expression profiles
and genetic screening assays to define their essential roles in
maintaining pluripotency in both mice and humans (Schöler
et al., 1990; Nichols et al., 1998; Avilion et al., 2003; Chambers
et al., 2003, 2007; Mitsui et al., 2003; Boyer et al., 2005; Loh et al.,
2006; Takahashi and Yamanaka, 2006; Masui et al., 2007; Wang
et al., 2012).
OCT4 interacts with other TFs to activate and repress gene
expression in mouse ESCs (Pesce and Schöler, 2001). For
example, OCT4 can heterodimerize with the SOX2 (HMG-box
transcription factor) to regulate gene expression level of many
genes in mouse ESCs (Yuan et al., 1995; Botquin et al., 1998;
Nishimoto et al., 1999).
However, the role of NANOG in the induction and
maintenance of pluripotency is not very clear. It may not
be essential in mouse PSCs (Chambers et al., 2007). The
low-level expression of NANOG (or even absent) in mouse
EpiSCs indicates that it may not be the essential part of the
core regulatory circuitry (Figure 2). However, it is reported to
stabilize PSCs and required for the development of pluripotency
in ICM in vivo (Silva et al., 2009). Its co-localization with
OCT4/SOX2 indicates its potential role in the maintenance of
pluripotency in both mice and humans. Reports show that the
major role is owned by OCT4 in the maintenance and induction
of pluripotency while under exceptional circumstances SOX2 and
NANOG may either be replaced by other substitutes or removed
without losing the pluripotency in PSCs.
Genome-scale location analysis for the identification of OCT4,
SOX2, and NANOG (OSN) target genes revealed that they co-
occupy a substantial portion of their target genes. Most common
target genes encode for the transcriptional factors, and many
of them are developmentally important homeodomain proteins
(Boyer et al., 2005; Loh et al., 2006). These studies suggested a
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regulatory model for the maintenance of self-renewal potential
and repressing differentiation by cooperative binding of OSN to
their promoters and thus auto-regulates their function (Boyer
et al., 2005; Loh et al., 2006).
Studies in mouse ESCs to understand regulatory network
maintaining pluripotency defined target promoter for a number
of TFs including OCT4, SOX2, NANOG (and others, e.g., KLF4,
c-MYC, Dax1, Rex1, Zpf281, and Nac1). These results indicated
two categories of promoters for the target genes on the basis of
the number of TFs bound to them (TFs no <4 indicates inactive
or repressed promoter; TFs no. >4 indicates promoter active in
the pluripotent state but gets repressed during differentiation).
Similar studies have been carried out by using chromatin
immunoprecipitation coupled with ultra-high-throughput DNA
sequencing (ChIP-seq) for identifying and mapping the locations
of some important TFs (including STAT3, NANOG, OCT4,
Smad1, SOX2, KLF4, Esrrb, Tcfcp2l1, Zfx, c-MYC, n-MYC, E2f1,
and CTCF). Also, identification of 2 transcription regulators p300
and Suz12 also revealed activation of a substantial fraction of
protein-coding, miRNA and non-coding RNA genes in ESCs. At
the same time, OSN interacts with the promoters of the genes
encoding lineage-specific regulators (Chen et al., 2008; Kim et al.,
2008).
Parallel studies established histone modification signatures as
crucial regulators of the gene expression in mammals. This is
further supported by specific roles defined for the histone three
lysine 4 and histone three lysine 27 trimethylations (H3K4me3
and H3K27me3, respectively) role in controlling gene regulation
in ESCs (Lee et al., 2004; Boyer et al., 2005; Bernstein et al., 2006;
Pan et al., 2007). The OSN are defined to bind promoters of
many lineages regulatory genes, and thus, both active (H3K4me3)
and repressive (H3K27me3) histone methyltransferase activities
(a bivalent state) possessed by ESCs is believed to facilitate
activation of developmental genes upon exit from pluripotency
(Bernstein et al., 2006). This capability of OSN to activate self-
renewal maintenance genes, while repressing lineage-specifying
regulators (i.e., Differentiation) is a major indicator for the
double hallmark features of ESCs.
PSCs are further classified as naïve or primed PSCs, and
different molecular markers can be defined to identify these states
among various types of PSCs. A set of diagnostic molecular
signatures for mouse PSCs that delineate their proximity to the
preimplantation ICM or post-implantation epiblast respectively
has been proposed amongst the various pluripotent states. These
distinct identification markers include X chromosome status in
female cells, global levels of DNA methylation, OCT4 enhancer
utilization, and expression levels of specific regulators’ group
defined as “naïve” TFs (for example a select group of TFs; KLF4,
KLF2, Esrrb, Tfcp2l1, Tbx3, and Gbx2; Tesar et al., 2007; Bao
et al., 2009; Guo et al., 2009; Silva et al., 2009; Dunn et al., 2014).
The set of above mentioned naïve TFs and Nanog are not
expressed (or very low expression level) in primed PSCs. They
are also capable of resetting primed PSCs in conjunction with
naïve pluripotency culture conditions. This reflects a regulatory
intersection between the naïve transcriptional network and
epigenetic resetting of both the DNA methylome and X
chromosome. Mouse ESCs derived from pre-implantation
blastocysts exhibit a ground state which is defined as the
configuration where the cells grow without depending on any
exogenous signaling stimuli, at the molecular level when cultured
along with the LIF and small molecule inhibitors of MEK and
Gsk3 kinases (2i/LIF conditions). These conditions are proposed
to stabilize the diagnostic signatures of pluripotency in ESCs
(Ying et al., 2008; Marks et al., 2012; Leitch et al., 2013).
There are distinct molecular diagnostic markers exhibited by
ESCs demonstrating their ground state, including the presence
of two active X chromosomes in female cells, low levels of DNA
methylation, high activity of OCT4 distal enhancer, and naïve
transcription factor expression. On the other hand, use of FGF
and ACTIVIN supports primed ESC state.While comparing with
the naïve ESCs, primed EpiSC is defined to have inactivated
forms of X-chromosome in female cells, a higher degree of DNA
methylation, high activity of proximal enhancer elements for
OCT4 gene and repression of naïve TFs.
There have been studies showing genome-wide DNA
methylation maps for different stages of PSCs, and it is proposed
that different molecular changes including DNA methylation
be highly dynamic during mammalian embryogenesis. These
developmental changes of ground state ESCs to EpiSCs (primed)
in vitro also resembles the changes during in vivo maturation
of preimplantation epiblast to post-implantation epiblast (Smith
et al., 2012; Boroviak et al., 2014).
Furthermore, the fine line existing between naïve and primed
states defining markers reveal a heterogeneous distribution of
various diagnostic markers among these states. It is evident
from the observation that both naïve PS markers (e.g., Chimera
formation capability) and post-implantation Epiblast marker
(e.g., High DNA methylation pattern) are exhibited by mouse
PSCs (Leitch et al., 2013). Similarly, this molecular heterogeneity
is observed in EpiSCs which are demonstrated to engraft
into posterior epiblast and possess diagnostic markers of post-
implantation stage indicating their primed PSC state (Wu et al.,
2015). While, region-selective EpiSCs are also reported to harbor
high cloning efficiency, indicating their naïve PS like properties.
These variable shows the need to redefine the various states
and their corresponding diagnostic markers more precisely and
that seems to incorporate a greater spectrum of functional and
molecular state markers. Similarly, the concept of ground state
PSCs appears to be incompletely defined. It is indicated by
the existing heterogeneity as demonstrated in gene expression
profiles, flow cytometry and replating experiments in single cell
studies (Kumar et al., 2014). This heterogeneity demonstrates
the coexistence of distinct molecular/functional states in mouse
ESCs (Kumar et al., 2014). This inherent metastability of PSCs is
further reflected by existing heterogeneity among individual cells.
Further, evenmuch homogenous ground state cultures have been
reported to bear variable TFs expression profile showing dynamic
states of PSCs that is both time and space related (Morgani et al.,
2013).
However, detailed information on the origin and consequence
of this heterogeneity is yet to be developed and by that time PSC
classification shall remain ambiguous due to the dynamic nature
of pluripotency defining markers. It is important to be noticed
that molecular markers may not strictly define the expected
Frontiers in Cell and Developmental Biology | www.frontiersin.org 6 November 2016 | Volume 4 | Article 134
Singh et al. Molecular and Functional Marker for Determining Pluripotency
functional development of PSCs. For example, mouse PSCs
were demonstrated not to get differentiated (an indication of
functional pluripotency) but exhibit all the keymolecular features
of pluripotency such as expression of core TFs in the absence
of DNA methylation and H3K27 methylation activities (Li et al.,
1992; Okano et al., 1999; Tsumura et al., 2006; Chamberlain et al.,
2008). This indicates that the pluripotency of any cell may only
be decided by carefully comparing molecular markers and their
capability to perform functionally.
Similar results are not available for the human ESCs which do
not grow in the absence of DNA methylation gene DNMT1 and
thus shown functional differences from the mouse ESCs (Liao
et al., 2015). Further, naïve PSCs are not affected by the epigenetic
regulatory factors which play important role in the primed PSC
state.
ASSESSMENT OF PLURIPOTENCY BY
VARIOUS FUNCTIONAL ASSAYS
Since the discovery of stem cells various advancements in
the study of pluripotency has been evolved from initial
embryological experiments to the in vitro generation of an array
of pluripotent states. Initial studies were done by using murine
ESCs (Evans and Kaufman, 1981) that remain an amenable and
convenient platform to study various developmental pathways
and identification of the major regulating factors of sustenance
of pluripotency. Subsequently, development of methods and
identification of different other types of pluripotent cells, such
as EG cells, EpiSCs, and IPSCs led to the comprehension of the
existing methodologies (Figure 3). In 1998, human ESCs were
defined for the first time (Thomson et al., 1998) and a wealth
of existing information about mouse pluripotent states served
as a reference point in defining human pluripotency. Recently,
the advent of iPSCs and more advanced technical resources
have provided some diagnostic tools for defining pluripotency as
discussed above.
The study of various types of PSCs and their capability to
give different developmental states has led to the accumulation
of many functional assays. These functional assays provide
stringent quality assessment tools for the evaluation of
pluripotency in both human and mice PSCs (Figure 3).
These experimental assays are majorly categorized as follows: (i)
in vitro differentiation into all three germ layers; (ii) capability
to form teratomas; (iii) chimerism of blastocysts; (iv) tetraploid
complementation; (v) transmission of germ line; and (vi)
chimera formation by using single pluripotent cell.
In vitro Differentiation Assays
Pluripotency is defined as the ability to give rise to cells from
all three germ layers of the body, which may be evaluated in
vivo (teratoma formation assay), and/or in vitro, by inducing the
differentiation of the ESCs into all three germ layers. Initially,
it was defined via the demonstration of aggregate formation
(embryoid bodies) in a hanging drop suspension culture method
(Wobus et al., 1984). Since then, various protocols have been
published showing the use of small molecules and growth factors
to induce differentiation into all three germ layers (Table 1).
However, in vitro differentiation is considered as the least
stringent test to establish the pluripotency.
Generally, in vitro differentiation assays are performed by
including stem cell culture (e.g., Embryoid bodies) in the
media containing a cocktail of differentiation inducing cytokines,
morphogens, or chemicals, and after that marker of a specific
target, tissues are identified to establish their differentiation
(Keller, 1995; Smith, 2001). For example, differentiation of neural
tissues (neurospheres) from neural stem cells (Lee et al., 2000;
Studer, 2001; Ferrari et al., 2010), cardiac bodies generation
from cardiac stem cells and their further differentiation into
cardiomyocytes, endothelial cells and smooth muscle cells
(Taubenschmid and Weitzer, 2012; Hoebaus et al., 2013)
and definitive endodermal differentiation from mouse ESCs
(Borowiak et al., 2009; Zhu et al., 2009). Mouse ESCs aggregates
are reported to resemble early stages of mouse embryonic
differentiation (for 7–8 days) which spontaneously develop into
cells of ecto-, meso-, and endodermal origins (Bader et al.,
2001). These embryonic bodies are highly useful in studying
cellular functions (by electrophysiology) and cell-cell interactions
(by using immunofluorescence assays). Whereas, pluripotency
assessment in human cells is inherently an intractable problem.
As it is described above, pluripotency evaluation in animal (e.g.,
mouse, rat, primates, etc.) involves their verification through
direct means i.e., PSCs are introduced into a developing embryo
and their differentiation potential can be directly determined by
evaluating the degree of chimerism and/or by determining the
organism’s viability that is derived from in vitro stem cells (Nagy
et al., 1993). This may not be applicable in humans because of
ethical reasons which would not allow these types of stringent
experimentation in the human system; thus indirect evidence
through biomarkers and correlative measures of differentiation
potential are the next best level of evidence for human stem cell
pluripotency. There are many pluripotency determining markers
being used for human cells which are chosen by the existing
evidence from other species. Defining pluripotency in human
system may be erroneous due to: (1) availability of small number
of markers and their use would erroneously validate potentially
abnormal stem cells which may also express the similar limited
set of markers as in normal stem cells, (2) despite some striking
orthologous similarities, the parallel comparison of mechanistic
insight from animals to the humans for the determination
of pluripotent features is problematic due to species-specific
differences in the cultured pluripotent phenotypes. In addition,
there are evolutionary structural variations in the transcriptional
communicating networks of human and animal cells. There
are few techniques such as, in silico genome-wide methods
(e.g., whole genome transcriptome profiles in combination with
complex biomarker models) which may be useful in defining the
ideal phenotype on a global scale (Skreb et al., 1971; Müller et al.,
2008, 2011; discussed in a later section).
Teratoma Formation Assays
This test is commonly used for defining the pluripotency in
mammals and being used for many decades (Stevens and
Little, 1954; Stevens, 1958, 1970; Solter et al., 1970; Skreb
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FIGURE 3 | The Various functional assessment approaches for Pluripotency. The most stringent tests for the determination of pluripotent cells that includes
the various functional assay that essentially rely on the capabilities of test pluripotent cell to self-renew and differentiate into all the three germ cell lineages including
ectoderm, mesoderm, and endoderm as mentioned in the text. Some of these assays would also explore the ability of test cells to give rise the whole organism and
give rise to a chimeric animal of desired characteristics.
et al., 1971; Evans and Kaufman, 1981). Moreover, it is a
widely accepted method in stem cell research and banking
(ISCBI, 2009; Gertow et al., 2011; Wesselschmidt, 2011). The
process can be summarized as the injection/infusion of test
cells (expected to be pluripotent) in animal models (mostly
mice) into various anatomical sites such as subcutaneous,
intramuscular, under the capsule of the kidney, or intra-testicular,
of immunocompromised mice and assessment of their potential
to develop a tumor. The pluripotency of the test cells is
judged on the basis of their ability to develop a tumor with
cells exhibiting characteristics of all three germ layers, namely
ectoderm (nerve/skin), mesoderm (bone, cartilage/muscle), and
endoderm (liver/gut; Brivanlou et al., 2003).
Although, used regularly and frequently, there have been
various issues related to the significance of this assay to define
pluripotency. The teratoma assay needs to be standardized
regarding graft site, the age of animal/mice, a number of cells or
graft size and the preparation cell details for various pluripotent
cell lines. The formation of teratomas is invariably influenced
by all these factors (Brivanlou et al., 2003; Hentze et al., 2009;
Wesselschmidt, 2011). Recently, a systematic evaluation of some
of these factors for two ESC lines has been proposed (Gropp et al.,
2012). Further, the assay is also regarded as time, cost and labor
intensive and raises ethical concerns (induce pain and suffering
of the animals used) for the utilization of the assay.
Apart from these issues, there are other technical drawbacks
such as inefficient histological analysis of teratomas, which may
lead to counting even incompletely reprogrammed cells that
generate masses with a superficial resemblance to teratomas yet
lack terminal three-germ-layer differentiation (Chan et al., 2009).
Also, there is a need for lineage tracing or analysis of donor cell-
specific marker to distinguish between host and donor cells. This
is important since most of the cell preparation uses matrices or
scaffold materials which can elicit inflammation or foreign body
reaction leading to the misinterpretation of tissue differentiation
(RIKEN, 2014).
Chimeras of Blastocysts
The term chimera (originated from Greek Xíµαιρα “she-goat
and sometimes namedmonster,” a fire-breathing creature bearing
body parts of three different animals, including a lion, a serpent,
and a goat) referred to a single organism generated from
the fusion of two (or more) genetically distinct cells from
a different origin. For most of the researcher generation of
mouse embryonic chimeras works as a well-established tool for
determining cell lineage commitment and pluripotency. Various
successful reports demonstrating experimental procedures for
chimeras’ generation by combining two or more preimplantation
embryos or, by introducing test cells (ESCs) into a host
embryo. This Chimera production technique gained popularity
for designing and generating knockout or knock in mice by using
genetically modified ESCs.
Initially (the 1960s), experimental mouse chimera were
generated by aggregating two or more whole 8-cell embryos
that give rise to normal-sized mice consisting tissues with
cells from both the parental embryos (Tarkowski, 1961; Mintz,
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1962). Mouse chimera production was also reported by injecting
isolated ICM cells into a host blastocyst cavity (Tarkowski, 1961;
Gardner and Munro, 1974; Bradley et al., 1984). Later on, ESCs
PGCs (Matsui et al., 1992) generated by somatic cell nuclear
transfer ESCs (ntESCs) (Wakayama et al., 2001) and iPSCs (Okita
et al., 2007) were also demonstrated to produce mice chimeras.
Further, mouse chimeras are also reported by using tetraploid
host embryos.
Apart from these conventional methods (e.g., aggregation
of embryos or embryonic cells derived from the same
developmental stage), mixing of embryonic cells from different
developmental stages can also result in the chimeric offspring
(Gearhart and Oster-Granite, 1981; Nagashima et al., 2004). For
example, isolated ICMs are shown to produce chimeras when
injected into the blastocoelic cavity of host blastocysts, and at the
same time when introduced in 8-cell or morula stage embryos
(Butler et al., 1987; Polzin et al., 1987; Roth et al., 1989; Nagy et al.,
1990; Picard et al., 1990).
In order to identify the contribution of the parental cells in
chimeric organism various genetic, biochemical and phenotypic
markers are developed. For example, the distinct coat color
pattern (a different strain of mice), electrophoretic variants of
the housekeeping enzyme glucose-6-phosphate isomerase has
frequently been used in earlier studies. In addition, DNA satellite
markers (strain-specific and first generation genetic marker;
Rossant et al., 1983) are well-reported for cell lineage tracking
based on in situ hybridization of histological samples that would
strike out the different origin of the chimera cells.
Histochemical staining methods to detect β-galactosidase
enzyme (E. coli lacZ gene and the epifluorescent microscopic
methods for the detection of green fluorescent protein are widely
used markers. There are new genetic markers also such as
microsatellites (short tandem repeats) being employed by a few
researchers (Tachibana et al., 2012). Experimental embryonic
chimeras have been reported in a number of species, including
sheep (Tucker et al., 1974), rats (Mayer and Fritz, 1974), rabbits
(Gardner and Munro, 1974), and cattle (Brem et al., 1984) and
more recently in nonhuman primates (Tachibana et al., 2012).
Despite the demonstration of ESCs or ESC-like cells expressing
pluripotencymarkers from several species, the germline chimeras
are reported only for the mouse and rat cells. Firstly, rat ESCs
expressing typical pluripotency markers (e.g., differentiate into
derivatives of all three germ layers) were reported to contribute
germline chimeras (Li et al., 2008) and their reintroduction into
early cleaving embryos was capable of inducing the chimera
formation (Li et al., 2008). Recent advances in iPSC technology
have been useful to generate PSCs from many species, including
rats (Liao et al., 2009), cattle (Han et al., 2011), sheep (Liu
et al., 2008, 2012), rhesus monkey (Liu et al., 2008), and pig
(Ezashi et al., 2009; Wu et al., 2009). Recently, porcine iPSCs
has been shown to exhibit chimera generating potential with
multiple tissue contribution for the three germ layers (West
et al., 2010). Generation of naïve-like porcine iPSCs has been
reported with the capabilities of contributing many organs in
the fetal chimera (such as head, atrium, ventricle, liver, brachial
arch, limb bud; Fujishiro et al., 2013). In humans, embryonic
chimerism is shown to occur by spontaneous aggregation of
two different zygotes/embryos and due to lack of detectable
features of chimerism, most of these conditions may not be
diagnosed. Therefore, chimerism in human is generally reported
by studies from either developmental anomalies or genotype/sex
discordance (Boklage, 2006; Mascetti and Pedersen, 2016).
Experimental human chimerism has been successfully
demonstrated by aggregation of fertilized embryos with
unfertilized embryos (parthenogenesis or androgenetic) or
by aggregation with the fertilized second polar body (Strain
et al., 1995; Malan et al., 2006). Thus, these studies have firmly
established the method for chimera production as a powerful
tool, and it is conceivable from a number of experimental
reports that high-quality PSCs would support the generation of
high-grade chimera. This is assessed by extensive colonization
of all embryonic cell lineages/tissues including germ line. On
the other hand, comparatively reduced embryonic viability and
small frequency of chimerism would indicate the relatively little
potency of the test cells.
Tetraploid Complementation Assays
The tetraploid complementation assay is a technique used to
construct genetically modified organisms, the study of mutation
related consequence of embryonic development, and in the study
of PSCs (Nagy et al., 1993; Kang et al., 2009).
This assay is based on the fact that the different lineage
potency is displayed by the two cellular constituents of the
(ESC ↔ Tetraploid embryo) chimera. On one hand, the ESCs
are developed into all structures in the fetus, while the tetraploid
cells produce the extraembryonic primitive endoderm tissue and
the trophectoderm.
One can carefully select genotypically different ESCs and
the tetraploid embryos (mutant versus wild type) to achieve
completely segregated cells (mutant cells vs. wild-type cells)
into two distinctive tissue compartments of the conceptus.
The method involves the production of a tetraploid cell (4n
chromosome) by fusing both the cells of a two-cell stage
embryo by applying an electrical current. This results in a
tetraploid cell which can divide and give rise to similar 4n
daughter cells. Although, this tetraploid embryo may develop
up to the blastocyst stage and can implant in the uterus wall
generating extraembryonic tissue (placenta) but it usually cannot
be developed into proper fetus due to its abnormal genetic
composition. The tetraploid complementation assay would use
a tetraploid embryo (either at the morula or blastocyst stage)
that is mixed with normal 2n ESCs (i.e., Test cells) from a
different organism to develop into the fetus. Fetus cells are
exclusively derived from the ESC (test cells) while the tetraploid
cells contribute to the generation of extra-embryonic tissues.
Therefore, this ESC-tetraploid embryo chimera becomes a useful
experimental tool to test the essentially required genes to
function in the embryonic versus extra-embryonic tissues for
the development of the concepts. This is one of the most
stringent assays to check the pluripotency and developmental
ability of the ES or iPSCs. The study of the manner in which
development of an embryo occurs helps to determine the effects
of a specific allele (wild type/mutant) on the development of the
organism. Abnormal development of the embryo from mutant
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tetraploid cells/wild type ESC composition would indicate defects
in the extra-embryonic tissues that are likely to be imposed
by the mutation of the extra-embryonic endoderm and the
trophectoderm only. Whereas, the development of an abnormal
embryo from mutant ESCs (in the epiblast-derived tissues)
and wild-type tetraploid cells (in the extra-embryonic tissues),
would be visible in the embryonic tissues or the extra-embryonic
mesoderm.
So, if there is a lethal mutation in the tetraploid cells, the
abnormality in the development of the organism would be due
to the defects in the extra-embryonic tissues. This allows us to
target the specific gene of interest so that themutation is removed
(wild type) and the potential of a liveborn organism can be
achieved.
Transmission of Germ Line
Germ line transmission is a process in which the ES derived
cells of a chimera result in the formation of reproductive cells
of the organism. As the germ cells are passed on to the inherited
offspring, it is known as germ line transmission. The assessment
of iPSCs for their capability for the formation of chimeras
contributing to all of the three germ layers, trophectoderm
and the gonads is done by studying the transmission of the
germ line. iPSCs possess in vitro differentiation potential and
morphological immunoreactivity but their plasticity still needs
to be tested for the formation of chimera which is an important
assay for pluripotency as the iPSCs derived from the transduction
of Oct4, Sox2, Klf4, and c-Myc possessed many pluripotent
characteristics but were unable to form chimeras which indicates
partial reprogramming (Esteban et al., 2009). The capability
of the chimera to breed and give rise to viable all-donor
pluripotent stem cell-derived offspring is a direct indicator of
their success and complete chimerism. The generation of live
chimeric offspring validates the potential of the iPSCs for the
application in stem cell therapies.
Technically, donor derived test PSCs are integrated into all
tissues of the later stages of viable embryos and those results
in the adult mice with chimeric tissue throughout their body
including germ line tissues. Further breeding of these chimeric
animals would lead to all donor PSCs-derived offspring (germ
line transmission) which is a robust indicator of chromosomal
integration and functional pluripotency.
Chimera Formation by Using Single
Pluripotent Cell
Chimeric or entirely embryonic stem (ES) cell-derived mice may
be produced by using Test cells into diploid (2n)/tetraploid (4n)
host blastocysts respectively to demonstrate their pluripotency.
As described by a number of successful experiments with
∼10–15 ESCs can be injected into the host blastocyst. Since
pluripotency stringently refers to the property of a single cell to
produce chimeras due to its widespread contribution. Analysis
of single PSCs-derived embryo would be of great significance
in determining clonal capacities of the test PSCs (Wang and
Jaenisch, 2004). However, single-cell chimerism and tetraploid
complementation assays are referred almost definitive tools for
determining pluripotency of any cell population, but as they
suffer from higher failure rates a researcher may not be able to
choose them as obvious tools.
DEFINING HUMAN PLURIPOTENT CELLS
ON THE BASIS OF MOLECULAR AND
FUNCTIONAL DIAGNOSTIC TOOLS
Human pluripotent cells (conventional) may be defined
on the basis of various molecular markers and functional
assays developed as “Primed” embryonic stem cell state. Since
it is shown to utilize the OCT4 proximal enhancer more
preferentially, and significantly high levels of DNA methylation.
It is reported to have inclined tendency to have an inactivated
X chromosome in female cell lines (Hanna J. et al., 2010). There
are reports regarding the assessment of human “naïve” PSCs by
blastocyst chimerism (Takashima et al., 2014; Theunissen et al.,
2014; Gafni et al., 2015). Despite ethical constraints on using
human ESCs in these studies limited experiments done with
both primed and altered human PSCs, which showed a little
contribution in chimera production on their infusion into mouse
pre-implantation embryos (Takashima et al., 2014; Gafni et al.,
2015).
However, studies done by using primate naïve iPSCs have
resulted to significant cross-species blastocyst chimerism. These
primate naïve iPSCs were injected into mouse blastocysts
resulting to the clonal contribution to the solid tissues (Fang et al.,
2014).
Further studies to demonstrate interspecies chimerism by
using primate ICM cells have not been successful in generating
blastocyst chimerism showing their different properties from
mouse ICM cells which readily produce chimeras (Tachibana
et al., 2012). Chen et al. described low-grade contribution to all
three germ layers by using altered primate PSCs (Chen et al.,
2015). But the more stringent test like high-grade contribution
and germline transmission are yet to be demonstrated to establish
naïve pluripotency in primate ESCs.
The most of these studies indicate the distinct behavior
of primate PSCs in chimeras studies. Therefore, interspecies
chimerism of human cells into mouse embryos would require
additional validation before its routine uses to assess human
stem cell potency. Recently, hiPSCs and hESCs have been
demonstrated to contribute to the normal mouse development by
using a stage-matching approach which involved transplantation
of hiPSCs/hESCs into gastrula-stage embryos. Both hiPSCs and
hESCs were reported to form interspecies chimeras with high
efficiency (Mascetti and Pedersen, 2016). The hiPSCs/hESCs well
colonized the embryo and differentiate into all the three primary
tissue layers. This tissue-specific fate post-transplantation defined
the potential of hPSCs to possess pluripotent characteristics
and provided mush awaited functional evidence that human-
mouse interspecies developmental competency may be useful in
defining their pluripotency by carefully matching their stage of
development.
The human stem-cell potency is also assessed by comparing
transcriptional and epigenetic molecular markers with the
pluripotent cells in human preimplantation embryos. As
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discussed in earlier sections, the degree of DNA methylation
and demethylation/remethylation in various PSCs is widely
accepted as a diagnostic signature for pre-implantation and
germline developmental stage derived cell in mammals (Deng
et al., 2009). There are reports of studies revealing the degree
of genomic methylation (hypomethylated vs. hypermethylated
DNA) which shown hypomethylated genome human pre-
implantation embryonic cells. Further, reports depicted a
remethylated genome in ICM derived cells and maintenance
of hypermethylated genome that is similar to mouse primed
PSCs in establishing human ESCs (Guo et al., 2014; Smith et al.,
2014). The epigenetic resetting is controlled by distinct regulatory
molecules and their interactions with each other in various states
of PSCs. Studies inmice naïve PSCs have highlighted a prominent
role of TFs such as KLF4, VTFCP2L1, ESRRB, TBX3, and
GBX2. Studies demonstrating single-cell RNA sequencing (RNA-
Seq) analysis of human preimplantation embryos (epiblast) and
hESCs to define gene expression signatures shown significant
differences in their transcriptomes (1498 differentially expressing
genes). Human preimplantation epiblast cells also express these
molecules. On the other hand, hESCs did not express them
showing similarities with mouse EpiSC states (Yan et al., 2013).
A simple comparison of the expression levels of specific TFs
in mice originated naïve cell with the human preimplantation
epiblast cells may not be sufficient to define their similar state of
development since some of these factors (e.g., KLF4) are absent
in human epiblasts.
Further, the interspecies comparison of other molecular
markers such as X chromosome inactivation timing and
epigenetic erosion in prime human ESCs has raised the
complexity (Silva et al., 2008; Okamoto et al., 2011; Anguera et al.,
2012; O’Leary et al., 2012), and identification of hES (ground
state or naïve PSCs) by comparing these molecular criteria with
the mouse ground state PSCs is not completely acceptable and
more specific marker may yet to be demonstrated for human
PSCs. While these discrepancies are increasingly being observed
by various research groups, a new concept of a metastable naïve
state of pluripotency is being suggested (Chan et al., 2013;
Valamehr et al., 2014; Ware et al., 2014). The uncertainty about
the role of X chromosome inactivation is further reflected by
studies from PSCs generated by Jaenisch and Smith Laboratories
showing expression of mouse ground state specific TFs (Silva
et al., 2008; Okamoto et al., 2011; Anguera et al., 2012; O’Leary
et al., 2012; Takashima et al., 2014; Theunissen et al., 2014; Gafni
et al., 2015). Declined DNA methylation pattern exhibited by
PSCs derived by Smith laboratories indicated their embryonic
preimplantation state, but other molecular markers such as
activities of OCT4 distal enhancer, and limited information
regarding the transgene-independent cell lines’ characterization
raise ambiguities about the stability of the reset state in these
human pluripotent cells (Takashima et al., 2014). Therefore,
due to these uncertainties among various molecular markers to
define the exact developmental state and hence their pluripotency
would be possible only after the direct derivation of ground
state ESCs from human embryos. These should be accompanied
by comprehensive experimental information regarding the
transition of these cells from totipotent to pluripotent states in
human and primates.
BIOINFORMATICS AND
COMPUTER-BASED METHODS FOR
PLURIPOTENCY DETERMINATION
As described in earlier sections PSCs may be useful in
various ways to understand human developmental stages, and
personalized regenerative medicine for most of the incurable
diseases. However, the direct functional assessment of their
propensity is cumbersome and even may not be feasible every
time. There are efforts reported from various research groups
regarding the development of high-throughput production
of human stem cells for use in regenerative medicine and
standardization of pluripotency assays by deploying a number
of approaches that promise to improve unbiased prediction of
the utility of both human-induced PSCs and ESCs by using
bioinformatics and gene expression profiling.
Genomic Analysis of PSCs
This is first method defined to evaluate the pluripotency of
PSCs by gene expression profiling through DNA microarrays.
It applied global molecular analysis approach for mapping
the transcriptome of PSCs (Sato et al., 2003; Sperger et al.,
2003; Bhattacharya et al., 2004; Suárez-Farinas et al., 2005)
and has become a standard assay of pluripotency in many
studies.
There are a number of algorithms that have been used
to classify cell lines into similar transcriptional states. Muller
et al. demonstrated a computational way (“Stem Cell Matrix”)
that allows the user to the classify cultured human stem
cells in various contexts of pluripotency, multipotency, and
differentiated cell types and thus, PSCs may be distinguished
from other stem cell types/differentiated cell types (Müller
et al., 2008). There has been significant progress in the
way these methods are being applied to define more subtle
differences in PSCs. The earlier comparisons of iPSCs and ESCs
indicated statistical differences between them (Maherali et al.,
2008; Chin et al., 2009; Soldner et al., 2009), and which was
visible even in their later stages with a significantly reduced
level. Recent advancements established global similarities with
small differences between iPSCs and hESCs (Marchetto et al.,
2009; Bock et al., 2011; Lister et al., 2011) such as changes
in gene expression signature in miRNA and long intergenic
noncoding RNA along with mRNA (Lakshmipathy et al.,
2010; Loewer et al., 2010; Stadtfeld et al., 2010). However,
a more comprehensive study would be required to define
the reasons behind these variations which may be due to
differences in growth parameters/conditions, laboratory-to-
laboratory variation (Newman and Cooper, 2010), heterogeneity
in iPSC quality (Maherali et al., 2008), or small sample sizes (Chin
et al., 2009).
One must be interested in developing such a method that
may be useful in identifying the pluripotency of any individual
cell or cell population. Since the gene expression profile is
highly variable among different pluripotent cells, it may be
difficult to establish such a signature expression profile, especially
when the sample size used in these gene expression studies is
relatively small and may not be sufficient to find consistent
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small observable differences among different PSCs (Bock et al.,
2011). Advancement in the availabilities of curated databases
with sufficiently large no. of samples should ensure the reliability
of these approaches.
Pluritest
Pluritest presents one of the excellent examples that can quantify
the extent to which experimental methodologies may perform
in order to convert a parental cell toward the target cell (Müller
et al., 2008). Since the assessment of the continuously expanding
larger data sets by the researchers through the newer techniques
such as machine learningmay be helpful in classifying the various
types of PSC lines available to the researchers. The Pluritest
makes the exact same comparisons by using an algorithm
that relies upon the use of training sets containing sufficiently
large dataset including huge numbers of (undifferentiated,
differentiated, normal, and abnormal) human stem cell lines
and tissues. These databases with larger sample sizes are used
to develop bioinformatics models for identifying stem cells’
pluripotency on the basis of gene expression measurements done
by DNA microarray (Müller et al., 2011). The bioinformatics
model for these assessments is generated by using two important
vectors that are calculated to categorize (i) pluripotent cells
vs. differentiated cells, and (ii) abnormal vs. normal gene
expression signature profiles. This calculation utilizes a large
training set of almost 500 samples curated for microarray data
quality and then consists results from microarray data originated
from the studies done on various types of pluripotent cells
e.g., hESCs, germ cell tumors, primary cell lines, and somatic
tissues microarray analysis. Pluritest algorithm has been reported
to distinguish the different test samples of germ cell tumors
from hESCs independently as well as distinguish reprogrammed
from partially reprogrammed iPSCs. Further, it is also useful
in identifying parthenogenetic stem cell lines and separating
them from hESCs which are assumed to be a manifestation of
differences at imprinted loci. This ability could be helpful in
distinguishing between abnormal and normal samples and also in
their categorization as undifferentiated/differentiated cell stage.
The algorithm has also been reported to be useful for iPSCs
characterization (MacArthur et al., 2012; Mariani et al., 2012;
Nazor et al., 2012). Similar models for mouse ESCs are also
developed showing their ability to calculate the reprogramming
efficiency in response to NANOG overexpression (MacArthur
et al., 2012; Mariani et al., 2012; Nazor et al., 2012). The
algorithm may find the further application, and various other
types of databases (e.g., epigenetic status or stem cell lines) may
be examined to define valuable information (Williams et al.,
2011). Although, the efficiency and sensitivity of these algorithms
to determine abnormalities e.g., copy number variations or
translocations is yet to be established. One approach to
improving this quality may be the inclusion of genomic integrity
tests and improving the variability of the training dataset used to
construct the model.
Comparison of Epigenetic Profiles of PSCs
Despite inconsistencies monitoring epigenetics may be sensitive
enough to define small changes and a more elaborated definition
for their functional consequences may be developed. For
example, together methylation mapping and gene expression
signatures methodologies by these sophisticated algorithms may
help in generating robust tools to infer the cell state. Bock
and colleagues shown minor yet significant differences in DNA
methylation and gene expression pattern in some IPS cell lines
but not in ESCs lines through a number of statistical tests
against preexisting datasets (Chin et al., 2009; Doi et al., 2009;
Stadtfeld et al., 2010; Bock et al., 2011; Theunissen et al., 2014).
As described in their studies by using a support vector machine
learning algorithm to classify the data, including both from
DNA methylation and gene expression data obtained from ESCs
lines (20 lines) and iPSCs lines (12 lines) this method efficiently
classifies ESCs cell lines. However, results with the iPSCs were
of moderate importance only when trying to classify iPSCs
lines. In brief, iPSCs specific gene signature was identified with
great accuracy (81%) and specificity (91%) but with moderate
sensitivity (61%). Considering the size of training datasets used
(for combined methylation and gene expression) in these studies
a significantly bigger dataset was used in similar methodologies
employed by Pluritest and its larger data set for training set
development in this method may also improve the predictions.
Newer Methods to Analyze the
Differentiation Potential of PSCs: The
Scorecard Approach
Since the right selection of most suitable undifferentiated cell
(PSCs) is a key to determine the success of developing a desired
cellular lineage for both the clinical and research purposes.
Presently used labor intensive methods e.g., teratoma formation
assay etc. are both time consuming and expensive. The different
in silico approached discussed so far mostly focus on the
identification and characterization of the status of differentiation
in PSCs andmay not be able to predict their ability to differentiate
into various required lineage cells. Bock et al. (2011) have tried to
fill this gap by demonstrating a method which predicts this ability
of PSCs by using combined gene expression data and epigenetic
measures with in vitro differentiation assays. In their report,
firstly a deviation scorecard is generated to evaluate existing data
for DNAmethylation and gene expression profiles. These profiles
are relative to a set of reference standard has lines which identify
deviated lines as reported by outlier detection methods.
This analysis would result in a number of genes (outliers) that
may be screened for their probable role in respective functional
assay’s performances (Boulting et al., 2011). For example, their
group assessed the data to identify genes associated with an
aberrant function for motor neuron when iPSCs is directed to
get differentiated into neuronal lineages. These studies could
highlight one putative gene GRM (glutamate receptor in a motor
neuron), and thus, the particular cell line may be ruled out on the
basis of this test result.
Further, a quantitative embryoid body assay through high-
throughput counting methods was used to develop quick
methods of highlighting the differentiation potential for PSCs
and develop a respective scorecard for the same. In a non-
directed embryoid differentiation assay (20 ESCs and 12 iPSC)
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RNA analysis was done to probe the expression level of 500
marker genes by Bock and colleagues. The results obtained
from these studies were used to generate a quantitative gene
expression profile from reference hESCs line derived embryoid
bodies. As described in their reports, the lineage scorecard
successfully detected and classified iPSCs lines based on their
ability to differentiate into ISL1-positive motor neurons in direct
differentiation assays.
In brief, prediction of differentiation fate in iPSCs could be
possible by the integration of themultiple high content functional
assay data. The linear scorecard approach is also beneficial
in predicting the possible ability of a particular cell line into
specific lineages on induction with appropriate factors/culture
environments through the selection of specific gene sets and
recalibration to reference standards. With the enhancement of
data (number of lines screened increases) identified potential
of this approach for the most frequent gene expression and
epigenetic aberrations may be achieved. In addition, frequent use
of these methods may benefit by reducing the cost and time taken
by conventional assay to decide the most appropriate lines for a
particular set of experiments or regime.
CONCLUSION
It is clear from the available information that pluripotency
is a dynamic state, and a large number of molecular factors
essentially regulate the fate of any developing cell. There are
many different types of molecular markers such as TFs, their
target gene promoters, miRNAs, noncoding RNAs, histone
modifiers proteins, and their corresponding gene expression,
which are being scrutinized by the global research community
to define the level of pluripotency. However, there have been
some discrepancies among these methods, and the reliability and
authenticity of these diagnostics markers may be liable to vary
for different cell types being evaluated by the researchers. Since
these molecular diagnostic molecules are yet to be optimized
for their ability to become more sensitive and accuracy of the
prediction made on the basis of the various bioinformatics
approaches would also be improved. Since then, only the
functional assays of various types, e.g., teratoma formation
assays, blastocyst chimerism, tetroid complementation assays,
etc. would remain the gold standard for the determination
of pluripotency. Recent advancements in the technology to
get pluripotent cells by reprogramming (iPSCs) and more
robust molecular techniques such as CHIP-seq, microarrays and
enhanced computing methods, together all these would further
enhance our understanding of the core regulatory elements
essential for the maintenance and induction of pluripotency in
various types of cells. Further, the capability to predict the most
obvious outcome by in silico tools when a PSC line is allowed
to differentiate would improve the clinical outcome in near
future.
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